Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are the same thing, dxa is the test that being used that quantifies lean body mass.
12 weeks from the last enrolled (July 12) is actually Oct 4. This is top line data, dxa scan at 12 weeks. Not the full trial results. The meeting is scheduled at a completely reasonable time interval to be compatible with results. Not saying it will happen, but the timing is lined up well. They originally said 2-4 weeks possible to clean up data. This would be one week to clean data (that they've had forever to refine as the trial has progressed). You seem to be spreading misinformation
Lol Greens. Trying my best to relax, countin hours til monday, take care buddy and best of luck to all
The trial was slated to enroll more than that, and they chose to complete enrollment with the current number. This was a decent length trial, they should have had plenty of time for interim analyses of data. You feel that they mistakenly stopped early and will not have statistically significance, and that will be the error?! Lol! I've worried about many things in this space, but that ain't one of them. Do some DD before you throw your money somewhere. I doubt you are worrying here for free tho
Thanks for the link. Very exciting. Especially bc both our drugs fit within the endocrine space, looking forward to the conference
Great call buddy! What a trading week... and not over yet
I feel that the ambiguity of this expert panel, and not clearly delineating it as the news day (which it is likely to be), is what is keeping us in check, and may ultimately be a huge help. I would be worried if we were too much higher that we wouldn't get far on news. If we can keep people a little skeptical, or remain mostly unknown for another week, we could really explode on news with our current goat and insider ownership structure.
This may be one of the few times that the lower we are before news, the higher we'll go on news. Roll of the dice brother. Take care
Hey Bull, I think you are likely correct. Really hard to say though. With the float pretty low, and seeing a lot of consistent buys over 1.20. I really don't think it would take too much attention to send this much higher, but I also can't imagine too many people taking a large legitimate interest in this a week before news. With the rise, big question always becomes if approval is baked into the price, and luckily I feel we are far from that, if results are better than marginal. Too many variables to guess. My gut feeling though, is that we won't stay at this level too long, and that it's not a maintainable level for various reasons, good and bad.
Strongly agree. Any things possible, but this seems like a calculated and smart approach to presenting (hopefully good) data
Defining the end date 10/9 will really help our cause here. Maybe I'm naive on this one, but calling together a panel of experts... seems to indicate that good news is afoot. Doubt we would need a panel to talk about the unmet needs of this market, if our drug isn't meeting some of them ;) hope I'm not proven wrong lol
Greatly agree it would be great if we went into news at $2.00+... could greatly mimic the price scenario of our peer gtxi with their recent news... imho. With additional bonus that our product is further along and the two don't really seem to be directly competing which might draw many others in that hold other companies in the sarm realm. Exciting times. Bid was 1.45 late after hours on Friday,hopefully a signal for the week ahead
Happy Friday all. Fun times ahead can't wait for next week!
Doesn't seem like many are selling, a good sign. The volume seems to only be slowing our ascent. Seems like people want shares around this price. If it gets too close to news without movement in price could shake some shares loose. I think many will be holding long term, based on ownership structure, so might get interesting
Read a great article about methodology of clinical research 2 or 3 days ago on a newsfeed I get. It discussed why placebo effect often is increased in later enrolled trial patients, and varies depending on how trials recruit at various stages of enrollment and are managed.
I speak Not at all about Viking specifically, and as of now have no qualms with they way they research and run trials... yet acknowledge that they are a young company. You can have a great drug, a great trial concept... but if the trial is designed or executed imperfectly, or less ideal endpoints or measurement instruments are used, results can be impacted.
Kind of like a dog show. You can have a great lookin dog, but if you send in pictures of the dog from odd angles or a bunch of dog butt photos, they won't accept your animal to the show haha.
Again, I am long on this and strongly believe this company may be onto somethin huge... I just want to give you a devils advocate argument for why some may decide to take some profits in the coming few weeks, and leave a little less on the chopping block for the big decision.
If I missed the boat explaining this, let me know. And again, I offer no specific criticisms of the endpoints they chose, as I am willing to be naive here, and assume that they knew which ones to choose, because they have had this drug in development and the secondary black market exposure for wayyyy longer than most drugs out there, and have had a long long loooong time to prepare for this moment and capture what they believe to be the best fit of data approaches
If went to 3.00 I'd make approx 200% on my common, maybe 175% on my warrants. If it went to 4.00 I'd make 300% on my common, but a little over 400% on my warrants. That's why 3.00 is my target, and why I will likely only hold warrants through news. Linear excess gains on warrants vs common for anything over 3.00. So anything over 3.00 and I'd be ecstatic. If this gets 5.00, I'm gonna start wearing a tophat 24/7 and quit my job!
my portfolio is 80% biotech, a lot of other stocks out there, one or two may get their day. The goal is surviving to keep playing the game, and be able to keep placing larger bets, imho. Odd results happen. Clinical trials are a funny game. I firmly believe we are heading for good news, but I also believe that clinical methodology sometimes temporarily defeats science, if that makes any sense.
I will continue holding way more warrants than a prudent man should... all the way through news. I sleep no easier friend. Bumpy roads ahead, enjoy the weekend all
Of my stake in Viking, 35% of that money in common, 65% warrants. Will eliminate most of my common before results, and continue holding vast majority of warrants. GLTA VKTX
Glad you asked... kind of prompted an intervention for me. Way too big a % of my portfolio. Currently 52%. Will probably be sitting closer to 35% within the next 2 weeks... went a little too crazy buying shares of common under 1.00 a few weeks back.
Very relevant post greens. Positive phase 2's can be significant catalysts. Especially given lack of available similar treatments on market for our product/class, esp w unique indication they are seeking initial approval for, further differentiating the product from other companies. Things hopefully get interesting over next two weeks. Being close to a month out is quickly becoming crunch time
historic gains coming? lol greens!!!
The additional data is from mouse testing. It's always possible that anima data may not translate into results for humans, but we have some human phase data that correlates already with a lot of what they are seeing. Without digging too deep into what if's, the data is great. I guess the question always in the back of my mind, is what are the downstream effects of these huge lipid reductions this accomplishes... like are their possible unforeseeable downstream effects. Will this be the holy grail of lipid lowering agents, or a drug that is used in small doses at periodic intervals to decompress the effects in people with serious glycogen storage diseases. That's the real question. And I don't think we may actually know the answer to that until phase 3 or later. The longer we go without unexpected weird side effects divulged, the higher the chances get that it may be closer to being a great all around lipid lowering agent, that could be a miracle drug in a different dose range for those poor individuals suffering from GSD. Time will tell. 5 weeks until possible sarm data... things should starting heating up over the next 2 weeks... let's hope.
Thoughts and prayers buddy, take care
Timing seems good on this PR. Don't think it will do much right now for price, but will likely make others more comfortable putting some money in during the run up to trial results coming up
Good PR out this morning. Really impressed with the magnitude of effect in the trial. Looks like things keep moving along. Nice to see this data out in a timely fashion! Hopefully you will sleep easier tonight greens (pardon my Thursday morning humor, but it is nice to see them stick to a timeline for a change lol) Have a good day all
http://ir.vikingtherapeutics.com/2017-09-07-Viking-Therapeutics-Announces-Presentation-of-Data-from-In-Vivo-Proof-of-Concept-Study-of-VK2809-in-Glycogen-Storage-Disease-Ia-GSD-Ia-at-the-13th-International-Congress-of-Inborn-Errors-of-Metabolism-ICIEM
Yes data collection expected to be over around end of this month (120 days of data collection after date last patient enrolled). Then 2-4 weeks for final data analysis, puts results around mid oct to beginning of nov
About 40 days until earliest likely news. Oh man. Enjoying what's left summer in NC. Have a good week all
Thank you for the link. Yes I saw the PR. Looks like it should be a little over a year from then before final results? Unless they choose to release any interim data I suppose, though it seems less likely in this setting. Either way, like the entry point. Will add more if it goes lower. I was a bit shocked to see how thinly it is being traded. Not necessarily a bad thing at this point though. Have a good one
Bull, I'm thinking mid oct to mid nov, conservatively. They said ? 2-4 weeks to clean up data, best case is mid oct to early nov. who knows maybe some early news. depends on how much data interpretation needed. price is hard buddy. higher than here, that's for sure. mostly depends on when we get and stay above 1.15. doesn't seem to take much volume to move us. there are a lot of other companies near this space. we may also benefit some on anyone else's news, as someone is likely to become relevant in this market in the next year. definitely a hold, but phase 2 results are tricky. could be 4-10 per share if the next 9 months treat us kindly, without huge stretches of imagination. just too much up in the air to have any idea. low float helps. the technology is more attractive than the company's prospects in selling medications imho. i view it as either a successful concept or not, because of how new it is. happy september
Just entered a position. If this turns out to be a legit company, this could be worth a fortunate at these prices. Here's to hoping
Feel that would be quite a long shot. New compound, semi-related to anabolics. Unless a drug is curing cancer, FDA seems very unlikely to bypass phase 3's. If phase 2's go well, it could save them time and energy in phase 3 though, in a number of ways. Great question though. Glad to have you still with us, hope summer is treating you well
Looks like the 1.5 million shares they just registered on friday (form 8-A12B) should give them the 50 mil market cap needed to qualify for Nasdaq uplist (more than enough actually, should make their cap now 74 million dollars)... interesting to see how nasdaq would impact trading
Nice to see some volume around this level. Clock is tickin'
That was an excellent analysis. Thank you for your time!
Not enough OS to do R/S anytime remotely soon. What would it accomplish anyways after this many R/S. anyone talking R/S at this point has no idea how and why they work.
Used to hold a fair amount of this stock, held through the opioid implant and got out shortly after. Feel that their implant tech is much better for other indications. Not that it doesn't make a solid opioid implant, but the current climate of addiction treatment leads me to believe that it's a product that addicts and docs don't really yet want... for about a million reasons beyond the scope of this msg. I'm excited for the malaria and Parkinson's drugs, but am concerned they will need to dilute to get them through the phases, and that the share price will remain in limbo until dilution is settled. I am planning to re-enter a short while after their next offering, be it 6 weeks or 6 months from now. Not bashing the stock, just bashing the current financials and the reality imposed by the drug they brought to market first, which thankfully finally was approved, and validated their tech. Also interested in post-launch infection stats for the the opioid implant. I don't think it will hold back Parkinson's or malaria, but it will shape the future of the opioid implant. Infection stats for regular docs inserting these post approval, not the infection stats from their own studies. Not saying there will be a difference, just saying I need it proven
Couldn't agree more buddy. The success of any of these companies trying to enter the SARM field will bring significant new attention. These are products people will actually want, which is hard to understate. Most drugs out there in development are just another medicine their doc may tell them they have to take, or offer glimpses of hope coupled with serious side effects. This stuff would sell itself, especially if the trial could show a boost to participants sense of 'well being' or energy... something we know that testosterone does (roid' rage aside lol). The next few weeks will probably be the last chance to secure a cheap and reasonable entry point, before the final leg... then all bets are off. Have a good one
I hope so, will continue buying anything at .055 and below. I think FDA update is inevitable within the next year, and that the regulatory environment for medical device may continue to soften. I agree the stock doesn't look like much at this time. I also find another R/S to be improbable in the short term... hence my entry points. Perhaps I'm wrong. Best of luck
Finishing green on almost 2.5x avg volume... even if based on 50K shares traded towards the end (1/3 the avg recent volume)... lol I'll take it
Nice buy volume today, maybe a sign of things to come
Doesn't seem they've attracted many sellers with the recent dip. Don't know if it would be financially lucrative for anyone to push it lower, with recent activity considered. I agree a move up is inevitable, and should be easily supported as soon as minor volume returns. Conservatively, I don't know if we'll make considerable moves higher until mid sept, early sept if we are lucky. We are right on the cusp of the month to month and a half waiting game in mid sept... At least on my end, time seems to be flying. I'm happy to finally have my my desired position, and overjoyed with what I picked up a few weeks back, and mostly glad to see the days ticking off the calendar. I feel that we might hover around 1.07/1.08 for awhile, before 1.12/1.13, then to the races. Guess time shall tell. Have a good week!
Roughy 60-80 days until Christmas morning... have a good day gents